Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents.

McLaughlin VV, Channick R, De Marco T, Farber HW, Gaine S, Galié N, Krasuski RA, Preston I, Souza R, Coghlan JG, Frantz RP, Hemnes A, Kim NH, Lang IM, Langleben D, Li M, Sitbon O, Tapson V, Frost A.

Chest. 2019 Nov 16. pii: S0012-3692(19)34214-X. doi: 10.1016/j.chest.2019.10.043. [Epub ahead of print]

2.

Practical management of riociguat in patients with pulmonary arterial hypertension.

Halank M, Tausche K, Grünig E, Ewert R, Preston IR.

Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619868938. doi: 10.1177/1753466619868938.

3.

Risk stratification and medical therapy of pulmonary arterial hypertension.

Galiè N, Channick RN, Frantz RP, Grünig E, Jing ZC, Moiseeva O, Preston IR, Pulido T, Safdar Z, Tamura Y, McLaughlin VV.

Eur Respir J. 2019 Jan 24;53(1). pii: 1801889. doi: 10.1183/13993003.01889-2018. Print 2019 Jan.

4.

Lower DHEA-S levels predict disease and worse outcomes in post-menopausal women with idiopathic, connective tissue disease- and congenital heart disease-associated pulmonary arterial hypertension.

Baird GL, Archer-Chicko C, Barr RG, Bluemke DA, Foderaro AE, Fritz JS, Hill NS, Kawut SM, Klinger JR, Lima JAC, Mullin CJ, Ouyang P, Palevsky HI, Palmisicano AJ, Pinder D, Preston IR, Roberts KE, Smith KA, Walsh T, Whittenhall M, Ventetuolo CE.

Eur Respir J. 2018 Jun 28;51(6). pii: 1800467. doi: 10.1183/13993003.00467-2018. Print 2018 Jun.

5.

Can we identify older people most vulnerable to living in cold homes during winter?

Sartini C, Tammes P, Hay AD, Preston I, Lasserson D, Whincup PH, Wannamethee SG, Morris RW.

Ann Epidemiol. 2018 Jan;28(1):1-7.e3. doi: 10.1016/j.annepidem.2017.11.008. Epub 2017 Dec 5.

PMID:
29425531
6.

Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report.

Elinoff JM, Agarwal R, Barnett CF, Benza RL, Cuttica MJ, Gharib AM, Gray MP, Hassoun PM, Hemnes AR, Humbert M, Kolb TM, Lahm T, Leopold JA, Mathai SC, McLaughlin VV, Preston IR, Rosenzweig EB, Shlobin OA, Steen VD, Zamanian RT, Solomon MA.

Am J Respir Crit Care Med. 2018 Jul 15;198(2):166-174. doi: 10.1164/rccm.201710-2093PP. No abstract available.

7.

Use of primary care data to predict those most vulnerable to cold weather: a case-crossover analysis.

Tammes P, Sartini C, Preston I, Hay AD, Lasserson D, Morris RW.

Br J Gen Pract. 2018 Mar;68(668):e146-e156. doi: 10.3399/bjgp18X694829. Epub 2018 Jan 29.

8.

Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study.

Preston IR, Channick RN, Chin K, Di Scala L, Farber HW, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF, Rubin LJ.

J Heart Lung Transplant. 2018 Mar;37(3):401-408. doi: 10.1016/j.healun.2017.09.024. Epub 2017 Oct 2.

PMID:
29096938
9.

Spironolactone-induced degradation of the TFIIH core complex XPB subunit suppresses NF-κB and AP-1 signalling.

Elinoff JM, Chen LY, Dougherty EJ, Awad KS, Wang S, Biancotto A, Siddiqui AH, Weir NA, Cai R, Sun J, Preston IR, Solomon MA, Danner RL.

Cardiovasc Res. 2018 Jan 1;114(1):65-76. doi: 10.1093/cvr/cvx198.

10.

Transglutaminase 2 in pulmonary and cardiac tissue remodeling in experimental pulmonary hypertension.

Penumatsa KC, Toksoz D, Warburton RR, Kharnaf M, Preston IR, Kapur NK, Khosla C, Hill NS, Fanburg BL.

Am J Physiol Lung Cell Mol Physiol. 2017 Nov 1;313(5):L752-L762. doi: 10.1152/ajplung.00170.2017. Epub 2017 Aug 3.

11.

Mechanism of Progressive Heart Failure and Significance of Pulmonary Hypertension in Obstructive Hypertrophic Cardiomyopathy.

Covella M, Rowin EJ, Hill NS, Preston IR, Milan A, Opotowsky AR, Maron BJ, Maron MS, Maron BA.

Circ Heart Fail. 2017 Apr;10(4):e003689. doi: 10.1161/CIRCHEARTFAILURE.116.003689.

12.

Bridging the science into practice.

Preston IR.

Pulm Circ. 2016 Dec;6(4):620. doi: 10.1086/688977. No abstract available.

13.

The prognostic significance of pulmonary arterial capacitance in pulmonary arterial hypertension: single-center experience.

Al-Naamani N, Preston IR, Hill NS, Roberts KE.

Pulm Circ. 2016 Dec;6(4):608-610. doi: 10.1086/688900.

14.

Macrophage migration inhibitory factor as a novel biomarker of portopulmonary hypertension.

DuBrock HM, Rodriguez-Lopez JM, LeVarge BL, Curry MP, VanderLaan PA, Zsengeller ZK, Pernicone E, Preston IR, Yu PB, Nikolic I, Xu D, Thadhani RI, Channick RN, Ananth Karumanchi S.

Pulm Circ. 2016 Dec;6(4):498-507. doi: 10.1086/688489.

15.

An international physician survey of chronic thromboembolic pulmonary hypertension management.

Gall H, Preston IR, Hinzmann B, Heinz S, Jenkins D, Kim NH, Lang I.

Pulm Circ. 2016 Dec;6(4):472-482. doi: 10.1086/688084.

16.

Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry.

Chung L, Fairchild RM, Furst DE, Li S, Alkassab F, Bolster MB, Csuka ME, Derk CT, Domsic RT, Fischer A, Frech TM, Gomberg-Maitland M, Gordon JK, Hinchcliff M, Hsu V, Hummers LK, Khanna D, Medsger TAJ, Molitor JA, Preston IR, Schiopu E, Shapiro L, Hant F, Silver R, Simms R, Varga J, Steen VD, Zamanian RT.

Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):106-113. Epub 2016 Nov 10.

PMID:
27908301
17.

Anti-coagulation in pulmonary arterial hypertension: the real blood and guts.

Preston IR, Farber HW.

J Thorac Dis. 2016 Sep;8(9):E1106-E1107. No abstract available.

18.

An international physician survey of pulmonary arterial hypertension management.

Preston IR, Hinzmann B, Heinz S, Gall H, Jenkins D, Kim NH, Lang I.

Pulm Circ. 2016 Sep;6(3):338-46. doi: 10.1086/688058. Erratum in: Pulm Circ. 2016 Dec;6(4):622.

19.

Plasma 12- and 15-hydroxyeicosanoids are predictors of survival in pulmonary arterial hypertension.

Al-Naamani N, Sagliani KD, Dolnikowski GG, Warburton RR, Toksoz D, Kayyali U, Hill NS, Fanburg BL, Roberts KE, Preston IR.

Pulm Circ. 2016 Jun;6(2):224-33. doi: 10.1086/686311.

20.

Response to Letter Regarding Article, "Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)".

Preston IR, Roberts KE, Miller DP, Sen GP, Selej M, Benton WW, Hill NS, Farber HW.

Circulation. 2016 May 17;133(20):e662. doi: 10.1161/CIRCULATIONAHA.116.022321. No abstract available.

PMID:
27185031
21.

Chronic Thromboembolic Pulmonary Hypertension: Experience from a Single Center in Mexico.

Al-Naamani N, Espitia H G, Velazquez-Moreno H, Macuil-Chazaro B, Serrano-Lopez A, Vega-Barrientos RS, Hill NS, Preston IR.

Lung. 2016 Apr;194(2):315-23. doi: 10.1007/s00408-016-9842-y. Epub 2016 Jan 9.

22.

Higher Estradiol and Lower Dehydroepiandrosterone-Sulfate Levels Are Associated with Pulmonary Arterial Hypertension in Men.

Ventetuolo CE, Baird GL, Barr RG, Bluemke DA, Fritz JS, Hill NS, Klinger JR, Lima JA, Ouyang P, Palevsky HI, Palmisciano AJ, Krishnan I, Pinder D, Preston IR, Roberts KE, Kawut SM.

Am J Respir Crit Care Med. 2016 May 15;193(10):1168-75. doi: 10.1164/rccm.201509-1785OC.

23.

Right heart catheterisation: best practice and pitfalls in pulmonary hypertension.

Rosenkranz S, Preston IR.

Eur Respir Rev. 2015 Dec;24(138):642-52. doi: 10.1183/16000617.0062-2015. Review.

24.

Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL).

Preston IR, Roberts KE, Miller DP, Sen GP, Selej M, Benton WW, Hill NS, Farber HW.

Circulation. 2015 Dec 22;132(25):2403-11. doi: 10.1161/CIRCULATIONAHA.115.018435. Epub 2015 Oct 28.

25.
26.

Reply: The Diastolic Pressure Gradient Does Not-and Should Not-Predict Outcomes.

Al-Naamani N, Preston IR, Paulus JK, Hill NS, Roberts KE.

JACC Heart Fail. 2015 Oct;3(10):846. doi: 10.1016/j.jchf.2015.07.007. No abstract available.

27.

Statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute.

Hemnes AR, Kiely DG, Cockrill BA, Safdar Z, Wilson VJ, Al Hazmi M, Preston IR, MacLean MR, Lahm T.

Pulm Circ. 2015 Sep;5(3):435-65. doi: 10.1086/682230.

28.

Alpha-Catulin Co-Localizes With Vimentin Intermediate Filaments and Functions in Pulmonary Vascular Endothelial Cell Migration via ROCK.

Bear MD, Liu T, Abualkhair S, Ghamloush MA, Hill NS, Preston I, Fanburg BL, Kayyali US, Toksoz D.

J Cell Physiol. 2016 Apr;231(4):934-43. doi: 10.1002/jcp.25185. Epub 2015 Sep 17.

PMID:
26377600
29.

Pulmonary hypertension trials: how can we do better?

Hill NS, Roberts K, Preston I.

Expert Rev Respir Med. 2015 Oct;9(5):551-8. doi: 10.1586/17476348.2015.1074040. Epub 2015 Aug 14.

PMID:
26290120
30.

Reply: Perspectives on Oral Pulmonary Hypertension Therapies Recently Approved by the U.S. Food and Drug Administration.

Hill NS, Badesch D, Benza RL, D'Eletto TA, Farber HW, Gomberg-Maitland M, Hassoun PM, Preston I.

Ann Am Thorac Soc. 2015 Jun;12(6):960. doi: 10.1513/AnnalsATS.201505-263LE. No abstract available.

PMID:
26075562
31.

Inhaled Therapies for Pulmonary Hypertension.

Hill NS, Preston IR, Roberts KE.

Respir Care. 2015 Jun;60(6):794-802; discussion 802-5. doi: 10.4187/respcare.03927. Review.

32.

Pulmonary Arterial Capacitance Is an Important Predictor of Mortality in Heart Failure With a Preserved Ejection Fraction.

Al-Naamani N, Preston IR, Paulus JK, Hill NS, Roberts KE.

JACC Heart Fail. 2015 Jun;3(6):467-474. doi: 10.1016/j.jchf.2015.01.013.

33.

The safety and effectiveness of riociguat to treat chronic thromboembolic pulmonary hypertension.

DeSouza SA, Preston IR.

Expert Rev Cardiovasc Ther. 2015 May;13(5):467-76. doi: 10.1586/14779072.2015.1027193. Epub 2015 Mar 22. Review.

PMID:
25797801
34.

[Updated treatment algorithm of pulmonary arterial hypertension].

Galiè N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, Klepetko W, McGoon MD, McLaughlin VV, Preston IR, Rubin LJ, Sandoval J, Seeger W, Keogh A.

Turk Kardiyol Dern Ars. 2014 Oct;42 Suppl 1:78-94. Turkish.

35.

Safety and efficacy of transition from inhaled treprostinil to parenteral treprostinil in selected patients with pulmonary arterial hypertension.

Preston IR, Feldman J, White J, Franco V, Ishizawar D, Burger C, Waxman AB, Hill NS.

Pulm Circ. 2014 Sep;4(3):456-61. doi: 10.1086/677360.

36.

Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration.

Hill NS, Badesch D, Benza RL, D'Eletto TA, Farber HW, Gomberg-Maitland M, Hassoun PM, Preston I.

Ann Am Thorac Soc. 2015 Feb;12(2):269-73. doi: 10.1513/AnnalsATS.201501-020AS.

PMID:
25590376
37.

Tissue transglutaminase promotes serotonin-induced AKT signaling and mitogenesis in pulmonary vascular smooth muscle cells.

Penumatsa K, Abualkhair S, Wei L, Warburton R, Preston I, Hill NS, Watts SW, Fanburg BL, Toksoz D.

Cell Signal. 2014 Dec;26(12):2818-25. doi: 10.1016/j.cellsig.2014.09.002. Epub 2014 Sep 15.

38.

Imatinib as rescue therapy in a patient with pulmonary hypertension associated with Gaucher disease.

Al-Naamani N, Roberts KE, Hill NS, Preston IR.

Chest. 2014 Sep;146(3):e81-e83. doi: 10.1378/chest.13-2795.

PMID:
25180747
39.

Updated treatment algorithm of pulmonary arterial hypertension.

Galiè N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, Klepetko W, McGoon MD, McLaughlin VV, Preston IR, Rubin LJ, Sandoval J, Seeger W, Keogh A.

J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D60-72. doi: 10.1016/j.jacc.2013.10.031. Review.

40.

New perspectives in long-term outcomes in clinical trials of pulmonary arterial hypertension.

Preston IR, Suissa S, Humbert M.

Eur Respir Rev. 2013 Dec;22(130):495-502. doi: 10.1183/09059180.00006413. Review.

41.

Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors.

Channick R, Preston I, Klinger JR.

Clin Chest Med. 2013 Dec;34(4):811-24. doi: 10.1016/j.ccm.2013.09.005. Review.

PMID:
24267306
42.

General supportive care.

Preston IR.

Handb Exp Pharmacol. 2013;218:153-60. doi: 10.1007/978-3-642-38664-0_6. Review.

PMID:
24092339
43.

Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry.

Chung L, Domsic RT, Lingala B, Alkassab F, Bolster M, Csuka ME, Derk C, Fischer A, Frech T, Furst DE, Gomberg-Maitland M, Hinchcliff M, Hsu V, Hummers LK, Khanna D, Medsger TA Jr, Molitor JA, Preston IR, Schiopu E, Shapiro L, Silver R, Simms R, Varga J, Gordon JK, Steen VD.

Arthritis Care Res (Hoboken). 2014 Mar;66(3):489-95. doi: 10.1002/acr.22121.

44.

Mineralocorticoid receptors in vascular disease: connecting molecular pathways to clinical implications.

McGraw AP, McCurley A, Preston IR, Jaffe IZ.

Curr Atheroscler Rep. 2013 Jul;15(7):340. doi: 10.1007/s11883-013-0340-x. Review.

45.

Differences between basal lung levels of select eicosanoids in rat and mouse.

Sagliani KD, Dolnikowski GG, Hill NS, Fanburg BL, Levy BD, Preston IR.

Pulm Circ. 2013 Jan;3(1):82-8. doi: 10.4103/2045-8932.109918.

46.

Comparison of acute hemodynamic effects of inhaled nitric oxide and inhaled epoprostenol in patients with pulmonary hypertension.

Preston IR, Sagliani KD, Roberts KE, Shah AM, Desouza SA, Howard W, Brennan J, Hill NS.

Pulm Circ. 2013 Jan;3(1):68-73. doi: 10.4103/2045-8932.109916.

47.

Properly diagnosing pulmonary arterial hypertension.

Preston IR.

Am J Cardiol. 2013 Apr 16;111(8 Suppl):2C-9C. doi: 10.1016/j.amjcard.2013.01.318.

PMID:
23558028
48.

Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension.

Sadoughi A, Roberts KE, Preston IR, Lai GP, McCollister DH, Farber HW, Hill NS.

Chest. 2013 Aug;144(2):531-541. doi: 10.1378/chest.12-2081.

49.

Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension.

Preston IR, Sagliani KD, Warburton RR, Hill NS, Fanburg BL, Jaffe IZ.

Am J Physiol Lung Cell Mol Physiol. 2013 May 15;304(10):L678-88. doi: 10.1152/ajplung.00300.2012. Epub 2013 Mar 1.

50.

Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey.

Meyer S, McLaughlin VV, Seyfarth HJ, Bull TM, Vizza CD, Gomberg-Maitland M, Preston IR, Barberà JA, Hassoun PM, Halank M, Jaïs X, Nickel N, Hoeper MM, Humbert M.

Eur Respir J. 2013 Jun;41(6):1302-7. doi: 10.1183/09031936.00089212. Epub 2012 Nov 8.

Supplemental Content

Loading ...
Support Center